John Farina

John Farina is a board member at Abcentra and a consultant/VP Pharmacology at Epigen Biosciences, Inc. John has over 20 years of experience in the pharmaceutical industry, specializing in respiratory disease and inflammation R&D and clinical development.

Farina founded Actimis Pharmaceuticals, Inc in January 2005 and served as its CSO until February 2018. During their tenure, they were responsible for the company's respiratory disease R&D, clinical development, site management, and business development. Under their leadership, the company successfully developed an IND and clinical PhI for an asthma asset, which was then out-licensed to a pharma company for further clinical development.

In June 2008, Farina founded Axikin Pharmaceuticals, Inc and served as its President and CSO until October 2017. At Axikin, they oversaw the company's respiratory disease and inflammation R&D, as well as clinical development, site management, and business development. John successfully developed 2 INDs and brought a respiratory asset into clinical PhI and IIa for asthma.

From October 1999 to December 2003, Farina served as Head of Respiratory TRA at ex-Bayer. In this role, they were responsible for the company's respiratory drug development program.

John Farina is a highly accomplished pharmaceutical executive with over 20 years of experience in the industry. John has a proven track record of successful drug development and has played a key role in bringing several respiratory assets into clinical trials. John's extensive knowledge and experience make him a valuable asset to any pharmaceutical company.